Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 21

1.

Preclinical modeling of a phase 0 clinical trial: qualification of a pharmacodynamic assay of poly (ADP-ribose) polymerase in tumor biopsies of mouse xenografts.

Kinders RJ, Hollingshead M, Khin S, Rubinstein L, Tomaszewski JE, Doroshow JH, Parchment RE; National Cancer Institute Phase 0 Clinical Trials Team.

Clin Cancer Res. 2008 Nov 1;14(21):6877-85. doi: 10.1158/1078-0432.CCR-08-0214.

PMID:
18980982
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Mechanisms of chemoresistance to alkylating agents in malignant glioma.

Sarkaria JN, Kitange GJ, James CD, Plummer R, Calvert H, Weller M, Wick W.

Clin Cancer Res. 2008 May 15;14(10):2900-8. doi: 10.1158/1078-0432.CCR-07-1719. Review.

PMID:
18483356
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Bioluminescence monitoring of intracranial glioblastoma xenograft: response to primary and salvage temozolomide therapy.

Dinca EB, Sarkaria JN, Schroeder MA, Carlson BL, Voicu R, Gupta N, Berger MS, James CD.

J Neurosurg. 2007 Sep;107(3):610-6.

PMID:
17886562
[PubMed - indexed for MEDLINE]
4.

ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models.

Donawho CK, Luo Y, Luo Y, Penning TD, Bauch JL, Bouska JJ, Bontcheva-Diaz VD, Cox BF, DeWeese TL, Dillehay LE, Ferguson DC, Ghoreishi-Haack NS, Grimm DR, Guan R, Han EK, Holley-Shanks RR, Hristov B, Idler KB, Jarvis K, Johnson EF, Kleinberg LR, Klinghofer V, Lasko LM, Liu X, Marsh KC, McGonigal TP, Meulbroek JA, Olson AM, Palma JP, Rodriguez LE, Shi Y, Stavropoulos JA, Tsurutani AC, Zhu GD, Rosenberg SH, Giranda VL, Frost DJ.

Clin Cancer Res. 2007 May 1;13(9):2728-37.

PMID:
17473206
[PubMed - indexed for MEDLINE]
Free Article
5.

Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel.

Sarkaria JN, Yang L, Grogan PT, Kitange GJ, Carlson BL, Schroeder MA, Galanis E, Giannini C, Wu W, Dinca EB, James CD.

Mol Cancer Ther. 2007 Mar;6(3):1167-74.

PMID:
17363510
[PubMed - indexed for MEDLINE]
Free Article
6.

Use of an orthotopic xenograft model for assessing the effect of epidermal growth factor receptor amplification on glioblastoma radiation response.

Sarkaria JN, Carlson BL, Schroeder MA, Grogan P, Brown PD, Giannini C, Ballman KV, Kitange GJ, Guha A, Pandita A, James CD.

Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2264-71.

PMID:
16609043
[PubMed - indexed for MEDLINE]
Free Article
7.

Temozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1.

Plummer ER, Middleton MR, Jones C, Olsen A, Hickson I, McHugh P, Margison GP, McGown G, Thorncroft M, Watson AJ, Boddy AV, Calvert AH, Harris AL, Newell DR, Curtin NJ.

Clin Cancer Res. 2005 May 1;11(9):3402-9.

PMID:
15867241
[PubMed - indexed for MEDLINE]
Free Article
8.

PARP inhibitors for cancer therapy.

Curtin NJ.

Expert Rev Mol Med. 2005 Mar 15;7(4):1-20. Review.

PMID:
15836799
[PubMed - indexed for MEDLINE]
9.

Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme.

Giannini C, Sarkaria JN, Saito A, Uhm JH, Galanis E, Carlson BL, Schroeder MA, James CD.

Neuro Oncol. 2005 Apr;7(2):164-76.

PMID:
15831234
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

MGMT gene silencing and benefit from temozolomide in glioblastoma.

Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R.

N Engl J Med. 2005 Mar 10;352(10):997-1003.

PMID:
15758010
[PubMed - indexed for MEDLINE]
Free Article
11.

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group.

N Engl J Med. 2005 Mar 10;352(10):987-96.

PMID:
15758009
[PubMed - indexed for MEDLINE]
Free Article
12.

Ablation of PARP-1 does not interfere with the repair of DNA double-strand breaks, but compromises the reactivation of stalled replication forks.

Yang YG, Cortes U, Patnaik S, Jasin M, Wang ZQ.

Oncogene. 2004 May 6;23(21):3872-82.

PMID:
15021907
[PubMed - indexed for MEDLINE]
13.

Novel poly(ADP-ribose) polymerase-1 inhibitor, AG14361, restores sensitivity to temozolomide in mismatch repair-deficient cells.

Curtin NJ, Wang LZ, Yiakouvaki A, Kyle S, Arris CA, Canan-Koch S, Webber SE, Durkacz BW, Calvert HA, Hostomsky Z, Newell DR.

Clin Cancer Res. 2004 Feb 1;10(3):881-9.

PMID:
14871963
[PubMed - indexed for MEDLINE]
Free Article
14.

Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361.

Calabrese CR, Almassy R, Barton S, Batey MA, Calvert AH, Canan-Koch S, Durkacz BW, Hostomsky Z, Kumpf RA, Kyle S, Li J, Maegley K, Newell DR, Notarianni E, Stratford IJ, Skalitzky D, Thomas HD, Wang LZ, Webber SE, Williams KJ, Curtin NJ.

J Natl Cancer Inst. 2004 Jan 7;96(1):56-67.

PMID:
14709739
[PubMed - indexed for MEDLINE]
Free Article
15.

Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide.

Stupp R, Dietrich PY, Ostermann Kraljevic S, Pica A, Maillard I, Maeder P, Meuli R, Janzer R, Pizzolato G, Miralbell R, Porchet F, Regli L, de Tribolet N, Mirimanoff RO, Leyvraz S.

J Clin Oncol. 2002 Mar 1;20(5):1375-82.

PMID:
11870182
[PubMed - indexed for MEDLINE]
16.

Overexpression of the DNA-binding domain of poly(ADP-ribose) polymerase inhibits rejoining of ionizing radiation-induced DNA double-strand breaks.

Rudat V, Bachmann N, K├╝pper JH, Weber KJ.

Int J Radiat Biol. 2001 Mar;77(3):303-7.

PMID:
11258844
[PubMed - indexed for MEDLINE]
17.

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse.

Yung WK, Albright RE, Olson J, Fredericks R, Fink K, Prados MD, Brada M, Spence A, Hohl RJ, Shapiro W, Glantz M, Greenberg H, Selker RG, Vick NA, Rampling R, Friedman H, Phillips P, Bruner J, Yue N, Osoba D, Zaknoen S, Levin VA.

Br J Cancer. 2000 Sep;83(5):588-93.

PMID:
10944597
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines.

Delaney CA, Wang LZ, Kyle S, White AW, Calvert AH, Curtin NJ, Durkacz BW, Hostomsky Z, Newell DR.

Clin Cancer Res. 2000 Jul;6(7):2860-7.

PMID:
10914735
[PubMed - indexed for MEDLINE]
Free Article
19.

Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and -proficient colon cancer cells to methylating agents.

Liu L, Taverna P, Whitacre CM, Chatterjee S, Gerson SL.

Clin Cancer Res. 1999 Oct;5(10):2908-17.

PMID:
10537360
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk